Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, which have serious and costly health consequences when left unchecked. Working to eradicate or treat bacterial infections such as invasive pneumococcal disease, Group A Strep, and Shigella is just the beginning. Our path to success is clear and well-defined, and Vaxcyte is set up to go the distance.
WHAT we do is every bit as important as HOW we do it! Our work together is guided by four enduring core values:
*RETHINK CONVENTION: We bring creative and intellectual diversity to every facet of the work we do in order to innovate and re-innovate the way vaccines are delivered.
*AIM HIGH: We embody our collectively audacious goal to courageously make the most complex biologics ever attempted to protect humankind.
*LEAD WITH HEART: Everyone leads at Vaxcyte with a kindness-first, inclusive approach to collaboration and vigorous debate that advances our business objectives.
*MODEL EXCELLENCE: The magnitude of our challenge requires our shared commitment to demonstrating integrity, accountability, equality and clarity across communications and decision making.
The Vice President, Insights & Analytics (I&A) is a newly created role responsible for building Vaxcyte’s commercial insights, analytics, and forecasting capabilities, beginning with the U.S. adult launch of VAX-31. This leader will oversee the existing Market Research and Competitive Intelligence team while establishing new commercial analytics capabilities, bringing these functions together into an integrated organization that informs strategic and operational decision-making across the Commercial organization.
The VP, I&A will translate market research, customer insights, competitive intelligence, claims data, and commercial performance data into actionable insights that inform strategy, resource allocation, forecasting, and execution. As a trusted advisor to commercial and executive leadership, this role will provide a clear, integrated view of market dynamics, customer needs, competitive developments, and business performance to identify risks and opportunities and support confident, data-driven decisions.
This role sits within the Commercial organization and will partner closely with the Commercial Leadership Team, including the Launch Lead and leaders across Marketing, Sales, Market Access, and Digital Enablement, as well as Finance, Medical Affairs, and Scientific Affairs. The role will own the business questions, analytical priorities, interpretation, and communication of insights, while partnering with Digital Enablement, which owns the systems, platforms, and AI-enabled tools that support data access and analytical capabilities at scale.
Reports to: Chief Commercial Officer
Location: US - Philadelphia, PA
Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy):
Hybrid (minimum of 3 days per week onsite)
The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $325,000 - $385,000. Salary ranges for non-California locations may vary.
This role is not eligible for relocation assistance.
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers.
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, our 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
We are re-engineering the way highly complex vaccines are made. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
In addition to our PCV franchise, our pipeline includes early-stage programs targeting Group A Strep, periodontitis and Shigella. At Vaxcyte, we are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
